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Abstract: Desymmetrization of the 
divinyl carbinol, 1,4-pentadien-3-ol, 
was accomplished by the asymmetric 
1,3-dipolar cycloaddition of azomethine 
imines based on a magnesium-mediated, 
multi-nucleating chiral reaction system 
utilizing diisopropyl (R,R)-tartrate as 
the chiral auxiliary. The corresponding 
optically active trans-pyrazolidines, 
each with three contiguous stereogenic 
centers, were obtained with excellent 
regio-, diastereo-, and 
enantioselectivity, with results as high 
as 99% ee. This reaction was shown to 
be applicable to both aryl- and 
aliphatic-substituted azomethine imines. 
The use of a catalytic amount of 
diisopropyl (R,R)-tartrate was also 
effective when accompanied by the 
addition of MgBr2.  
 
Introduction 
The desymmetrization of achiral or meso compounds has proved to 
be a powerful technique in asymmetric synthesis, since it allows the 
formation of multiple stereogenic centers in one symmetry-breaking 
operation. This strategy has therefore attracted considerable 
attention with regard to the synthesis of optically active natural 
products or biologically active substances.[1] Group selective 
desymmetrization of divinyl carbinols and their derivatives is one of 
the most promising strategies for the production of new optically 
active alcohol derivatives containing an unreacted olefinic moiety, 
which could be a useful functional group during further 
transformations. The Katsuki-Sharpless epoxidation of 1,4-
pentadien-3-ols results in desymmetrization to yield epoxy alcohols 
which are versatile synthetic intermediates for the preparation of 
oxygen-functionalized biologically active compounds.[2,3] However, 
techniques which allow the desymmetrization of divinyl carbinols as 
a means of forming multiple stereocenters along with the formation 
of new C–C bonds are quite limited. 
Pyrazolidines are biologically active[4] and are versatile 
synthetic intermediates for the synthesis of nitrogen-containing 
chemicals, and various enatioselective syntheses of pyrazolidines by 
asymmetric 1,3-dipolar cycloaddtions have been reported.[5] 
Recently, we developed the asymmetric 1,3-dipolar cycloaddition of 
azomethine imines to allyl and homoallyllic alcohols, utilizing either 
stoichiometric or catalytic amounts of diisopropyl (R,R)-tartrate 
[(R,R)-DIPT] to furnish trans-pyrazolidines with high regio-, 
diastereo-, and enantioselectivity.[6] In order to construct multi-
chiral centers via our 1,3-dipolar cycloaddition of azomethine 
imines, enantiotopic differentiation of the two vinyl groups of 
prochiral divinyl carbinols is required, which is challenging. Herein 
we describe the desymmetrization of a divinyl carbinol, 1,4-
pentadien-3-ol, by the asymmetric 1,3-dipolar cycloaddition of 
azomethine imines, utilizing (R,R)-DIPT as the chiral auxiliary. 
Results and Discussion 
We initially investigated the 1,3-dipolar cycloaddition of 1-
benzylidene-3-oxopyrazolidin-1-ium-2-ide (2a) to 1,4-pentadien-3-
ol (1), based on a magnesium-mediated, multi-nucleating chiral 




In this process, a mixture of 1.0 equiv of 1 and 1.0 equiv of 
(R,R)-DIPT is treated with 3.0 equiv of MeMgBr in MeCN, 
followed by the addition of 1.0 equiv of azomethine imine 2a, after 
which the reaction mixture is held at 80 °C for 2 d. It was gratifying 
to observe that the desymmetrization proceeded under these 
conditions to give only one diastereomer of the corresponding 
pyrazolidine 3a with excellent enantioselectivity (Table 1, Entry 
1).[9] The use of the alternate solvent EtCN further enhanced the 
reaction yield (Entry 2). The halogen in the Grignard reagent also 
had an effect;[10] when nBuMgCl was used, the yield of the 
cycloadduct 3a was significantly improved (Entry 3).  
The desymmetrization of 1,4-pentadiene-3-ol (1) by the 
asymmetric cycloaddition of several azomethine imines 2b-2f was 
subsequently investigated in EtCN at 80 °C. The aryl-substituted 
azomethine imines 2b and 2c afforded the corresponding 
cycloadducts 3b and 3c with excellent enantioselectivity and 
complete regio- and diastereoselectivity in each case (Entries 4 and 
5). The cycloaddition of the pentyl-substituted azomethine imine 2d 
proceeded in an enantioselective manner, although a significant 
quantity of the by-product 4 (Figure 2) was obtained (Entry 6). The 
use of an excess of the carbinol 1 slightly improved the reaction 
yield (Entry 7). The cycloaddition of the cyclohexyl-substituted and 
t-butyl-substituted azomethine imines 2e and 2f also afforded the 
cycloadducts 3e and 3f with enantioselectivities of 99% and 98% ee, 
respectively (Entries 8 and 9). 
Table 1. 
Figure 2. 
To increase the efficiency of the procedure, we subsequently 
employed only a catalytic amount of (R,R)-DIPT as the chiral 
auxiliary.[6c] In this revised procedure, 1.5 equiv of nBuMgCl and 
the azomethine imine 2a were added successively to a mixture of 
1.1 equiv of 1, 0.2 equiv of (R,R)-DIPT, and 1.0 equiv of MgBr2 in 
EtCN and the reaction mixture was held at 80 °C for 5 d. Although 
the corresponding pyrazolidine 3a was obtained with 84% ee, the 
reaction proceeded quite slowly and yield was insufficient (Table 2, 
Entry 1). When MeMgBr was used in place of nBuMgCl, both 
enantioselectivity and chemical yield were increased (Entry 2). The 
addition of the magnesium salt was confirmed to be effective by 
comparing the enantioselectivity shown in Entry 2 with the result 
obtained in the absence of MgBr2 (Entry 3). 
The catalytic asymmetric cycloadditions of a number of other 
azomethine imines 2b-2f to the divinyl carbinol 1 were attempted in 
EtCN at 80 °C. The aryl-substituted azomethine imines 2b and 2c 
once again resulted in excellent enantioselectivity, even when 
applied in this modified catalytic process (Entries 4 and 5). The 
cycloaddition of pentyl-substituted azomethine imine 2d proceeded 
quite slowly to give the desired cycloadduct 3d in low yield in 
addition to the dimerized by-product 4 (Entries 6 and 7). The 
cycloaddition of cyclohexyl- and t-butyl-substituted azomethine 
imines 2e and 2f still afforded the corresponding pyrazolidines in 
good chemical yields with excellent enantioselectivity (Entries 8 and 
9). 
Table 2. 
The absolute configuration of the enantiomerically rich 3a (98% 
ee) was determined by treating this product with (1S)-camphanic 
chloride and Et3N in the presence of a catalytic amount of 4-(N,N-
dimethylamino)pyridine (DMAP) in CH2Cl2 to generate the 
corresponding ester 5 (99%) (Equation 1). Recrystallization gave 
diastereomerically pure 5 and the absolute stereochemistry at each 
of its three chiral centers was determined to be R,R,R by X-ray 
crystallographic analysis of a single crystal (Figure 3). From this 
result, the absolute configuration of 3a was confirmed as 5R,7R,1’R. 
The absolute configurations tentatively assigned to the other 
products were 5R,7R,1’R in the case of 3b, 3c, 3e, and 3f and 
5S,7R,1’R in the case of 3d, which has the same configurational 




We have previously reported that the 1,3-dipolar cycloaddition 
of 2a to homoallylic alcohols proceeded with excellent 
enantioselectivity.[6c] In this study, we also examined the 
desymmetrization of the homoallylic-type dialkenyl carbinol, 1,6-
heptadien-4-ol (6). The corresponding cycloadduct 7 was obtained 
with moderate enantioselectivity and the diastereoselectivity was 
low (Equation 2).  
Equation 2. 
While the precise mechanism by which this reaction proceeds is 
not yet clear, we propose the following transition state model. In this 
model, the carbonyl oxygen of 2, rather than the imine nitrogen, 
coordinates with the magnesium salt of DIPT (Figure 4). In the case 
of the T2 transition state, steric repulsion between the pro-R vinyl 
group and the azomethine imine skeleton disturbs the cycloaddition 
to the pro-S vinyl group. As a result, it is more likely that the T1 
state actually occurs, since in this state it is primarily the pro-R 
olefin which approaches the azomethine imine, giving the R,R,R 
product. During the reaction of the homoallylic-type alcohol 6, the 
extension of the side chains by one carbon compared to the divinyl 
carbinol 1 makes these chains more flexible, especially around C4, 
and reduces steric hindrance effects. The diastereoselection between 
the T3 and T4 states is therefore less than that between the T1 and T2 
states, although the exact stereochemistry of the major product of 
this reaction has not yet been determined.  
 
Figure 4. 
The pyrazolidines could be transformed to the 1,3-diamine 
derivatives.[11] We simply demonstrated the reduction of 3a by the 
use of Raney nickel. Although only the double bond was reduced 
under the ordinary atmosphere, N–N bond was successfully cleaved 
to give 8 under a pressured hydrogen atmosphere. Furthermore, the 
attractive reductive or oxidative transformation of 3a was realized. 
The reduction of amide moiety with LiAlH4 afforded a one-of-a-
kind tricyclic hexahydro-1-oxa-2a1,4a-diazacyclopentapentalene 
skeleton 9 in good yield. The use of large excess amount of LiAlH4 
induced reductive ring opening of oxazolidine moiety to give a 
bicyclic hydrazine derivative 10. In addition, the hydrazide moiety 
in 3a was chemoselectively oxidized by treatment with mCPBA to 
furnish a unique N-oxide 11 while olefinic moiety remained intact 
(Scheme 1). The novel structures of 9, 10, and 11 might have 
potential as new types of organocatalysts, for example.   
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Scheme 1.  
Conclusion 
An attractive and unique reaction scheme allowing the 
desymmetrization of 1,4-pentadien-3-ol by the asymmetric 1,3-
dipolar cycloaddition of azomethine imines has been developed. 
This process generates highly enantiomerically pure pyrazolidines 
possessing three contiguous stereogenic centers as single 
diastereomers. The obtained pyrazolidines contain a double bond 
and a hydroxyl group on the side chain, both of which might allow 
further functionalization. The present method would be useful for 




1H NMR spectroscopy was performed in CDCl3 using a JEOL ECS 400 NMR (400 
MHz) spectrometer. Chemical shifts (δ) were determined relative to TMS (δ = 0 ppm) 
as an internal standard. 13C NMR spectroscopy was performed in CDCl3 on a JEOL 
ECS 400 NMR (100 MHz) spectrometer and chemical shifts (δ) were determined 
relative to CDCl3 (δ = 77.0 ppm) as an internal standard. IR spectra were acquired on a 
JASCO FT/IR-230 spectrometer. Melting points were determined on a micro-melting 
apparatus (Yanagimoto–Seisakusho) and were uncorrected. The specific optical 
rotations were recorded on a JASCO DIP-370 spectrometer. HPLC was performed 
using chiral column with JASCO PU980 plus JASCO UV970. X-ray crystallography 
was performed on a Rigaku/MSC Mercury diffractometer with graphite-
monochromated Mo-Kα radiation. Elemental analysis was performed on a Yanaco 
CHN Corder MT-5 elemental analyzer. Mass spectra were obtained using JMS-700 and 
JMS-T100TD mass spectrometers. All solvents were distilled prior to use and stored 
over drying agents. Merck silica gel 60 PF254 (Art. 7749), Cica silica gel 60N spherical 
neutral (37563-84), and JAIGL-SIL (s-043-15) were used for thin-layer 
chromatography (TLC), flash column chromatography, and recycle HPLC, respectively. 
The retention factors (Rf) of various compounds were determined by TLC.  
 
 
The following is a representative procedure for the stoichiometric asymmetric 1,3-
dipolar cycloaddition of azomethine imine 2e (Table 1, Entry 8): 
To a EtCN (3 mL) solution of 1,4-pentadien-3-ol (1) (42 mg, 0.50 mmol) and (R,R)-
DIPT (117 mg, 0.50 mmol) was added butylmagnesium chloride (1.50 mmol, 1.70 mL 
of 0.91 M solution in THF) at 0 °C under an argon atmosphere and the mixture was 
stirred for 1 h. Azomethine imine 2e (90 mg, 0.50 mmol) was added to the resulting 
solution and the mixture was stirred for 0.5 h at rt and then 3 d at 80 °C. The reaction 
was quenched by the addition of a sat. aqueous solution of NH4Cl and the mixture was 
subsequently extracted with CHCl3. The combined extracts were dried over Na2SO4 and 
condensed under reduced pressure. The residue was purified by column 
chromatography (SiO2, hexane/AcOEt = 1:1 to 0:1) to give the corresponding 
pyrazolidine 3e (106 mg, 80%) with a selectivity of 99% ee. 
In a similar manner, the pyrazolidines 3a–3d, 3f, and 7 were prepared from azomethine 
imines 2a–2d, 2f. 
(5R,7R)-7-((R)-1-Hydroxyallyl)-5-phenyltetrahydropyrazolo[1,2-a]pyrazol-1(5H)-one 
(3a) 
3a (120 mg, 93%) was obtained as a solid. Rf = 0.65 (AcOEt); [α]25D +55 (c 1.2, EtOH); 
The ee was determined to be 99% by HPLC (Daicel CHIRALCEL OD-H, hexane/EtOH 
= 10:1, 0.5 mL/min, 254 nm, major 33 min and minor 25 min); m.p. 76–77 °C 
(recrystallized from EtOH); 1H NMR (CDCl3, 400 MHz): δ = 2.40 (dt, 1H, J = 13.3, 9.6 
Hz), 2.49 (ddd, 1H, J = 13.3, 7.8, 5.0 Hz), 2.74–2.86 (m, 2H), 2.91–3.01 (m, 1H), 3.38 
(dd, 1H, J = 9.2, 7.8 Hz), 3.55 (dd, 1H, J = 9.2, 6.4 Hz), 3.89 (ddd, 1H, J = 9.6, 8.7, 5.0 
Hz), 4.31–4.36 (m, 1H), 5.29 (d, 1H, J = 10.5 Hz), 5.46 (d, 1H, J = 17.0 Hz), 5.82 (ddd, 
1H, J = 17.0, 10.5, 7.3 Hz), 6.54 (br, 1H), 7.31–7.39 (m, 5H); 13C NMR (CDCl3, 100 
MHz) δ = 36.4, 41.2, 50.3, 59.8, 68.5, 75.0, 118.7, 127.1, 128.2, 128.7, 136.1, 137.3, 
165.9; IR (KBr) 3189, 3063, 3033, 2978, 2931, 2865, 1649, 1455, 1421, 1366, 1339, 
1315, 1146, 1067, 1001, 929, 760, 700 cm–1; elemental analysis calcd (%) for 
C15H18N2O2: C, 69.74; H, 7.02; N, 10.85; found: C, 69.75; H, 7.11; N, 10.79. 
(5R, 7R)-7-((R)-1-Hydroxyallyl)-5-(4-methoxyphenyl)tetrahydropyrazolo[1,2-
a]pyrazol-1(5H)-one (3b) 
3b (141 mg, 98%) was obtained as an oil; Rf = 0.60 (AcOEt) ; [α]25D +53 (c 1.4, EtOH); 
The ee was determined to be 99% by HPLC (Daicel CHIRALCEL OD-H, hexane/EtOH 
= 10:1, 0.5 mL/min, 254 nm, major 36 min and minor 29 min); 1H NMR (CDCl3, 400 
MHz): δ = 2.37 (dt, 1H, J = 13.3, 9.2 Hz), 2.45 (ddd, 1H, J = 13.3, 7.8, 5.0 Hz), 2.73–
2.84 (m, 2H), 2.86–2.99 (m, 1H), 3.33–3.37 (m, 1H), 3.48–3.53 (m, 1H), 3.81 (s, 3H), 
3.88 (ddd, 1H, J = 9.2, 8.7, 5.0 Hz), 4.32 (dd, 1H, J = 8.7, 7.4 Hz), 5.28 (d, 1H, J = 10.5 
Hz), 5.45 (d, 1H, J = 17.0 Hz), 5.82 (ddd, 1H, J = 17.0, 10.5, 7.4 Hz), 6.50 (br, 1H), 
6.89 (d, 2H, J = 8.7 Hz), 7.25 (d, 2H, J = 8.7 Hz); 13C NMR (CDCl3, 100 MHz): δ = 
36.5, 41.2, 50.2, 55.3, 60.0, 68.2, 75.3, 114.1, 118.8, 128.4, 129.0, 136.2, 159.6, 166.1; 
IR (neat) 3271, 2838 1651, 1612, 1514, 1444, 1420, 1359, 1302, 1248, 1176, 1151, 
1033, 997, 833, 767 cm–1; HRMS (FAB+): m/z calcd for C16H21N2O3: 289.1552: 
[M+H]+; found: 289.1555.   
(5R, 7R)-5-(4-Chlorophenyl)-7-((R)-1-hydroxyallyl)tetrahydropyrazolo[1,2-a]pyrazol-
1(5H)-one (3c) 
3c (144 mg, 97%) was obtained as an oil. Rf = 0.65 (AcOEt); [α]25D +58 (c 1.4, EtOH); 
The ee was determined to be 99% by HPLC (Daicel CHIRALCEL OD-H, hexane/EtOH 
= 10:1, 0.5 mL/min, 254 nm, major 35 min and minor 27 min); 1H NMR (CDCl3, 400 
MHz): δ = 2.34 (dt, 1H, J = 13.3, 9.2 Hz), 2.48 (ddd, 1H, J = 13.3, 7.3, 4.6 Hz), 2.75–
2.84 (m, 2H), 2.91–3.02 (m, 1H), 3.35–3.40 (m, 1H), 3.52 (dd, 1H, J = 9.2, 7.8 Hz), 
3.87 (ddd, 1H, J = 9.2, 8.7, 4.6 Hz), 4.33 (dd, 1H, J = 8.7, 7.3 Hz), 5.29 (d, 1H, J = 10.6 
Hz), 5.45 (d, 1H, J = 17.4 Hz), 5.81 (ddd, 1H, J = 17.4, 10.6, 7.3 Hz), 6.49 (br, 1H), 
7.28 (d, 2H, J = 8.2 Hz), 7.34 (d, 2H, J = 8.2 Hz); 13C NMR (CDCl3, 100 MHz): δ = 
36.4, 41.3, 50.3, 59.8, 67.8, 74.7, 118.7, 128.4, 128.8, 133.9, 135.96, 136.03, 165.7; IR 
(KBr) 3404, 3049, 2977, 2920, 2834, 1657, 1496, 1446, 1421, 1305, 1264, 1234, 1135, 
1091, 1028, 937, 849, 731, 711 cm–1; elemental analysis calcd (%) for C15H17N2O2Cl: C, 
61.54; H, 5.85; N, 9.57; found: C, 61.28; H, 6.01; N, 9.38. 
(5S,7R)-7-((R)-1-Hydroxyallyl)-5-pentyltetrahydropyrazolo[1,2-a]pyrazol-1(5H)-one 
(3d) 
3d (33 mg, 33%) was obtained as an oil. Rf = 0.60 (AcOEt) ; [α]25D +36 (c 0.3, EtOH); 
The ee was determined to be 97% by HPLC (Daicel CHIRALCEL OD-H, hexane/EtOH 
= 20:1, 0.5 mL/min, 254 nm, major 34 min and minor 24 min); 1H NMR (CDCl3, 400 
MHz): δ = 0.89 (t, 3H, J = 6.4 Hz), 1.28–1.36 (m, 7H), 1.50–1.60 (m, 1H), 2.03 (ddd, 
1H, J = 12.8, 9.6, 9.2 Hz), 2.19 (ddd, 1H, J = 12.8, 7.3, 5.0 Hz), 2.44–2.51 (m, 1H), 
2.72–2.82 (m, 2H), 2.92–3.04 (m, 1H), 3.53–3.59 (m, 1H), 3.65 (ddd, 1H, J = 9.2, 8.7, 
5.0 Hz), 4.22 (dd, 1H, J = 8.7, 7.3 Hz), 5.28 (d, 1H, J = 10.6 Hz), 5.42 (d, 1H, J = 17.4 
Hz), 5.80 (ddd, 1H, J = 17.4, 10.6, 7.3 Hz), 6.67 (br, 1H); 13C NMR (CDCl3, 100 MHz): 
δ = 13.9, 22.4, 25.7, 31.8, 32.0, 36.6, 38.0. 51.5, 59.7, 65.0, 75.0, 118.5, 136.3, 165.1; 
IR (neat) 3431, 2980, 2931, 1741, 1660, 1453, 1376, 1263, 1131, 1105, 1031, 701 cm–1; 
HRMS (FAB+): m/z calcd for C14H25N2O2: 253.1916: [M+H]+; found: 253.1920. 
(5R*,6R*,7R*)-6-Butyl-7-(3-oxopyrazolidine-1-yl)-5-pentyltetrahydropyrazolo[1,2-
a]pyrazol-1(5H)-one (4) 
Rf = 0.30 (AcOEt); m.p. 153–154 °C (recrystallized from AcOEt); 1H NMR (CDCl3, 
400 MHz): δ = 0.88–0.92 (m, 6H), 1.24–1.43 (m, 11H), 1.51-1.69 (m, 3H), 2.05–2.11 
(m, 1H), 2.36–2.52 (m, 3H), 2.63–2.73 (m, 2H), 3.05–3.14 (m, 1H), 3.56 (dt, J = 11.0, 
7.8 Hz, 1H), 3.64–3.76 (m, 2H), 4.48 (d, J = 5.0 Hz, 1H), 7.80 (br, 1H); 13C NMR 
(CDCl3, 100 MHz): δ = 13.9, 14.0, 22.4, 22.8, 25.7, 29.4, 30.2, 31.0, 31.1, 31.8, 32.2, 
47.9, 49.7, 50.8, 72.5, 81.0, 174.1, 175.6; IR (KBr): 3154, 3070, 2954, 2930, 2898, 
2858, 1682, 1471, 1420, 1344, 1313, 1289, 1273, 1179, 1095, 1081, 966, 767, 663 cm–1; 
elemental analysis calcd (%) for C18H32N4O2: C, 64.24; H, 9.60; N, 16.65; found: C, 
63.94; H, 9.66; N, 16.49. Crystal data: C18H32N4O2, FW. 336.48, monoclinic, P21/n, a = 
10.0073(8), b = 8.1555(6), c = 23.033(2) Å, V = 1845.6(3) Å3, β = 100.960(2)°, Z = 4. 
Dcalc = 1.211 g/cm3. R = 0.037 (Rw = 0.046) for 2936 reflections with I > 3.00σ(I) and 
217 variable parameters. 
CCDC 951615 (4) contains the supplementary crystallographic data for this paper. 
These data can be obtained free of charge from The Cambridge Crystallographic Data 
Centre via www.ccdc.cam.ac.uk/data_request/cif. 
(5R,7R)-5-Cyclohexyl-7-((R)-1-hydroxyallyl)tetrahydropyrazolo[1,2-a]pyrazol-1(5H)-
one (3e)  
3e (106 mg, 80%) was obtained as an oil. Rf = 0.65 (AcOEt); [α]25D +16 (c 1.1, EtOH); 
The ee was determined to be 99% by HPLC (Daicel CHIRALCEL OD-H, hexane/EtOH 
= 20:1, 0.5 mL/min, 254 nm, major 37 min and minor 28 min); 1H NMR (CDCl3, 400 
 4 
MHz): δ = 0.88–1.02 (m, 2H), 1.08–1.25 (m, 3H), 1.36–1.43 (m, 1H), 1.66–1.77 (m, 
5H), 2.06–2.11 (m, 2H), 2.35 (dd, 1H, J = 8.2, 6.9 Hz), 2.70–2.82 (m, 2H), 2.92–2.59 
(m, 1H), 3.53–3.62 (m, 2H), 4.23 (dd, 1H, J = 8.7, 6.9 Hz), 5.26 (d, 1H, J = 10.1 Hz), 
5.42 (d, 1H, J = 17.0 Hz), 5.80 (ddd, 1H, J = 17.0, 10.1, 6.9 Hz), 6.82 (br, 1H); 13C 
NMR (CDCl3, 100 MHz): δ = 25.7, 25.8, 26.1, 28.6, 30.0, 35.3, 36.5, 40.5, 53.3, 59.5, 
69.8, 74.2, 118.2, 136.1, 164.3; IR (neat) 3258, 2925, 2852, 1658, 1449, 1421, 1353, 
1297, 1285, 1158, 1049, 997, 929, 894, 714 cm–1; HRMS (FAB+): m/z calcd for 
C15H25N2O2: 265.1916: [M+H]+; found: 265.1911. 
(5R,7R)-5-tert-Butyl-7-((R)-1-hydroxyallyl)tetrahydropyrazolo[1,2-a]pyrazol-1(5H)-
one (3f) 
3f (67 mg, 56%) was obtained as an oil. Rf = 0.75 (AcOEt) ; [α]25D –13 (c 0.9, EtOH); 
The ee was determined to be 99% by HPLC (Daicel CHIRALCEL OD-H, hexane/EtOH 
= 20:1, 0.5 mL/min, 254 nm, major 34 min and minor 27 min); 1H NMR (CDCl3, 400 
MHz): δ = 0.90 (s, 9H), 1.94–2.06 (m, 2H), 2.36 (dd, 1H, J = 8.7, 6.9 Hz), 2.72 (dd, 1H, 
J = 15.1, 7.8 Hz), 2.83 (dt, 1H, J = 13.3, 8.2 Hz), 2.93–3.02 (m, 1H), 3.45 (td, 1H, J = 
8.7, 8.2 Hz), 3.60 (t, 1H, J = 8.7 Hz), 4.23 (dd, 1H, J = 8.7, 6.9 Hz), 5.27 (d, 1H, J = 
10.5 Hz), 5.44 (d, 1H, J = 16.9 Hz), 5.82 (ddd, 1H, J =  16.9, 10.1, 6.9 Hz), 6.96 (br, 
1H); 13C NMR (CDCl3, 100 MHz): δ = 26.3, 26.9, 33.2, 33.9, 36.7, 55.0, 60.1, 73.7, 
118.1, 135.9, 163.9; IR (neat) 3237, 2958, 2870, 1657, 1452, 1422, 1299, 1252, 1152, 
1132, 1052, 994, 929 cm–1; HRMS (FAB+): m/z calcd for C13H23N2O2: 239.1760: 
[M+H]+; found: 239.1754.   
7-(2-Hydroxy-4-penten-1-yl)-5-phenyltetrahydropyrazolo[1,2-a]pyrazol-1(5H)-one (7) 
A 16:9 mixture of diastereomers (40 mg, 28%) was obtained as an oil. The mixture was 
further separated by recycle HPLC (AcOEt/EtOH = 15:1) to give the major and minor 
products: Major diastereomer: Rf = 0.50 (AcOEt); [α]25D +41 (c 0.22, EtOH); The ee 
was determined to be 78% by HPLC (Daicel CHIRALPAK IA, hexane/EtOH = 10:1, 
0.5 mL/min, 254 nm, major enantiomer of the major diastereomer 35 min and its minor 
enantiomer 27 min); 1H NMR (CDCl3, 400 MHz): δ = 1.77 (dd, 1H, J = 14.6, 6.9 Hz), 
2.25–2.35 (m, 3H), 2.42 (ddd, 1H, J = 12.8, 6.4, 3.7 Hz), 2.52–2.68 (m, 3H), 2.87 (td, 
1H, J = 10.1, 9.6 Hz), 3.68–3.75 (m, 1H), 3.75–3.83 (m, 1H), 3.98 (br, 1H), 4.16–4.23 
(m, 1H), 5.00–5.04 (m, 1H), 5.12 (d, 1H, J = 10.1 Hz), 5.13 (d, 1H, J = 17.0 Hz), 5.87 
(ddt, 1H, J = 17.0, 10.1, 7.3 Hz), 7.13–7.39 (m, 5H); 13C NMR (CDCl3, 100 MHz): δ = 
36.1, 40.9, 42.6, 44.4, 48.9, 51.0, 67.3, 68.9, 117.7, 127.5, 128.3, 128.8, 134.7, 137.3, 
166.1; IR (KBr): 3387, 3069, 2978, 2924, 2845, 1662, 1495, 1370, 1342, 1305, 1146, 
1072, 1034, 996, 915, 755, 703 cm–1; HRMS (FAB+): m/z calcd for C17H23N2O2: 
287.1760: [M+H]+; found: 287.1756. Minor diastereomer: Rf = 0.60 (AcOEt); [α]25D 
+13 (c 0.13, EtOH); The ee was determined to be 68% by HPLC (Daicel CHIRALCEL 
OD-H, hexane/EtOH = 10:1, 0.5 mL/min, 254 nm, major enantiomer of the minor 
diastereomer 27 min and its minor enantiomer 20 min); 1H NMR (CDCl3, 400 MHz) δ = 
1.74 (ddd, 1H, J = 13.7, 10.1, 4.6 Hz), 1.90 (ddd, 1H, J = 13.7, 10.1, 3.2 Hz), 2.22–2.37 
(m, 3H), 2.39–2.50 (m, 2H), 2.66 (ddd, 1H, J = 12.8, 8.7, 6.0 Hz), 3.05 (q, 1H, J = 10.1 
Hz), 3.16 (td, 1H, J = 10.1, 3.2 Hz), 3.85–3.94 (m, 2H), 4.31–4.40 (m, 1H), 4.46 (br, 
1H), 5.09 (d, 1H, J = 10.1, Hz), 5.11 (d, 1H, J = 17.0 Hz), 5.89 (ddt, 1H, J = 17.0, 10.1, 
7.4 Hz), 7.21–7.28 (m, 2H), 7.32–7.40 (m, 3H)； 13C NMR (CDCl3, 100 MHz): δ = 
34.8, 41.6, 42.9, 43.0, 46.2, 50.4, 66.1, 67.7, 117.1, 127.8, 128.3, 128.9, 135.1, 137.1, 
169.6; IR (neat)：3385, 3068, 2962, 2921, 2849, 1663, 1604, 1495, 1418, 1368, 1302, 
1261, 1141, 1087, 1031, 915, 802, 756, 703 cm–1; HRMS (FAB+): m/z calcd for 
C17H23N2O2: 287.1760: [M+H]+; found: 287.1757. 
The following is a representative procedure for the catalytic asymmetric 1,3-dipolar 
cycloaddition of azomethine imine 2e (Table 2, Entry 8): 
To a suspension of Mg turning (12 mg, 0.50 mmol) in THF (3 mL), 1,2-dibromoethane 
(144 mg, 0.50 mmol) was added at rt under an argon atmosphere and the mixture was 
stirred for 3 h until all Mg turning was converted to MgBr2. To the solution, a EtCN (3 
mL) solution of 1,4-pentadien-3-ol (1) (47 mg, 0.55 mmol) and (R,R)-DIPT (24 mg, 
0.10 mmol) was added. After the addition of methylmagnesium bromide (0.75 mmol, 
0.76 ml of 0.99 M solution in THF) at 0 °C, the mixture was stirred for 1 h. Azomethine 
imine 2e (90 mg, 0.50 mmol) was added to the resulting solution and the mixture was 
stirred for 0.5 h at rt and then 2 d at 80 °C. The reaction was quenched by the addition 
of a sat. aqueous solution of NH4Cl and the mixture was subsequently extracted with 
CHCl3. The combined extracts were dried over Na2SO4 and condensed under reduced 
pressure. The residue was purified by column chromatography (SiO2, hexane/AcOEt = 




A CH2Cl2 (1 mL) solution of the pyrazolidine 3a (85 mg, 0.33 mmol, 98% ee) was 
added to a mixture of (S)-camphanic chloride (217 mg, 1.00 mmol), triethylamine (0.14 
mL, 1.00 mmol), and 4-(dimethylamino)pyridine (16 mg) in CH2Cl2 (1 mL) at rt under 
a nitrogen atmosphere and the mixture was stirred for 3 d at rt. Solvent was evaporated 
and the residue was partitioned between AcOEt and water, followed by extraction with 
AcOEt. The combined extracts were dried over Na2SO4. After evaporation of the 
solvent, the residue was purified by TLC on SiO2 (hexane/AcOEt = 1:1) to afford 5 
(143 mg, 99%) as a solid. Diastereomerically pure 5 was obtained by recrystallization 
(Et2O/hexane). Rf = 0.40 (hexane/AcOEt = 1:1); [α]D25 +49 (c 1.43, CHCl3); m.p. 164–
165 °C (recrystallized from Et2O/hexane); 1H NMR (CDCl3, 400 MHz): δ = 0.95 (s, 
3H), 1.08 (s, 3H), 1.11 (s, 3H), 1.67 (ddd, 1H, J = 13.7, 9.6, 4.6 Hz), 1.90–2.02 (m, 1H), 
1.92 (ddd, 1H, J = 13.3, 10.5, 4.6 Hz), 2.02 (ddd, 1H, J = 13.7, 9.2, 4.6 Hz), 2.38–2.53 
(m, 3H), 2.60–2.67 (m, 1H), 2.95–3.05 (m, 1H), 3.21–3.27 (m, 1H), 3.77–3.84 (m, 1H), 
4.25–4.32 (m, 1H), 5.48 (d, 1H, J = 10.5 Hz), 5.57 (d, 1H, J = 16.0 Hz), 5.90–5.99 (m, 
2H), 7.22–7.25 (m, 2H), 7.32–7.38 (m, 3H); 13C NMR (CDCl3, 100 MHz): δ = 9.4, 16.4, 
16.6, 28.7, 30.4, 34.7, 38.3, 47.2, 54.0, 54.6, 67.1, 73.7, 77.2, 90.8, 121.1, 127.5, 128.2, 
128.6, 131.0, 136.9, 165.8, 168.4, 177.8; IR (KBr) 2968, 2841, 1779, 1755, 1666, 1431, 
1415, 1320, 1258, 1168, 1110, 1062 cm–1; elemental analysis calcd (%) for C25H30N2O5: 
C 68.47, H 6.90, N 6.39; found: C 68.14, H 6.88, N 6.39. Crystal data: C25H30N2O5, FW. 
438.52, monoclinic, C2, a = 28.417(2), b = 8.1392(7), c = 9.7820(7) Å, V = 2262.3(3) 
Å3, β = 90.608(1)°, Z = 4. Dcalc = 1.287 g/cm3. R = 0.035 (Rw = 0.046) for 4763 
reflections with I > 3.00σ(I) and 290 variable parameters. 
CCDC 948017 (5) contains the supplementary crystallographic data for this paper. 
These data can be obtained free of charge from The Cambridge Crystallographic Data 
Centre via www.ccdc.cam.ac.uk/data_request/cif. 
(5R,7R)-7-((R)-1-Hydroxypropyl)-5-phenyltetrahydropyrazolo[1,2-a]pyrazol-1(5H)-one  
To a MeOH (1.4 mL) solution of 3a (99% ee, 52 mg, 0.20 mmol), potassium hydroxide 
(27 mg, 0.50 mmol) in H2O and nickel/aluminum alloy (421 mg) were subsequently 
added at room temperature.[13] The mixture was stirred at room temperature for 3 d and 
filtered through a bed of Celite and the filtrate was condensed under reduced pressure. 
The residue was purified by column chromatography (SiO2, AcOEt only) to give 
(5R,7R)-7-((R)-1-hydroxypropyl)-5-phenyltetrahydropyrazolo[1,2-a]pyrazol-1(5H)-one 
(18 mg, 35%) as an oil. Rf = 0.70 (AcOEt only); [α]D25 +117 (c 0.18, EtOH); 1H NMR 
(CDCl3, 400 MHz): δ = 1.05 (t, J = 7.3 Hz, 3H), 1.41–1.52 (m, 1H), 1.57–1.64 (m, 1H), 
2.39–2.51 (m, 2H), 2.76–2.91 (m, 3H), 3.35–3.39 (m, 1H), 3.61–3.65 (m, 1H), 3.76 (td, 
J = 8.7, 2.8 Hz, 1H), 3.83–3.89 (m, 1H), 6.29 (brs, 1H), 7.26–7.29 (m, 5H); 13C NMR 
(CDCl3, 100 MHz): δ = 9.4, 26.6, 36.3, 41.1, 49.9, 61.0, 68.7, 73.3, 127.2, 128.3, 128.8, 
138.0, 166.3; IR (neat) 3270, 2930, 1650, 1460, 1420, 1160, 980 cm–1; HRMS (DART): 
m/z calcd for C15H21N2O2: 261.1603: [M+H]+; found: 261.1593.   
(6S,8S)-8-((R)-1-Hydroxypropyl)-6-phenyl-1,5-diazocan-2-one (8) 
A EtOH (2 mL) solution of 3a (99% ee, 52 mg, 0.20 mmol) was combined with Raney 
nickel (W-2) (100 mg, wet weight). The mixture was stirred at room temperature under 
50 atm of hydrogen for 3 d.[11b] The mixture was filtered through a bed of Celite and 
condensed under reduced pressure. The residue was purified by column 
chromatography (SiO2, AcOEt only ~ AcOEt/MeOH = 10:1) to give 8 as a solid. Rf = 
0.30 (AcOEt/MeOH = 5:1); [α]D25 –19 (c 0.27, CHCl3); m.p. 97.5–99.0 °C 
(recrystallized from AcOEt); 1H NMR (CDCl3, 400 MHz): δ = 0.97 (t, J = 7.4 Hz, 3H), 
1.41–1.48 (m, 2H), 1.92–1.99 (m, 1H), 2.22–2.34 (m, 2H), 2.36–2.43 (m, 1H), 2.54–
2.62 (m, 1H), 2.76–2.83 (m, 1H), 3.08–3.15 (m, 1H), 3.21–3.27 (m, 1H), 3.52–3.56 (m, 
1H), 3.55 (br, 1H), 4.08 (td, J = 4.1, 10.5 Hz, 1H), 7.17–7.32 (m, 5H). Signal of one OH 
or NH proton was not observed clearly; 13C NMR (CDCl3, 100 MHz): δ = 10.2, 28.3, 
30.3, 32.8 (2C), 43.6, 56.6, 75.8, 126.0, 128.2, 128.5, 141.6, 172.7; IR (KBr) 3310, 
2960, 1640, 1440, 1300, 1100, 1000 cm–1; HRMS (DART): m/z calcd for C15H23N2O2: 
263.1760: [M+H]+; found: 263.1771.   
 (2R,2aR,4R)-4-Phenyl-2-vinylhexahydro-2H-1-oxa-2a1,4a-
diazacyclopenta[cd]pentalene (9) 
To a suspension of LiAlH4 (12 mg, 0.30 mmol) in THF (1.0 mL) was added a THF (0.5 
mL) solution of 3a (99% ee, 39 mg, 0.15 mmol) at 0 °C and the resultant suspension 
was stirred for 2 h under refluxing. After the reaction was cooled to 0 °C, H2O (0.01 
mL), 30% NaOH aq (0.01 mL), and H2O (0.03 mL) were subsequently added, followed 
by stirring for 30 min at rt. The mixture was filtered through a bed of Celite and the 
filtrate was condensed under reduced pressure. The residue was purified by TLC on 
SiO2 (hexane/AcOEt = 1:1) to afford 9 (32 mg, 88%) as an oil. Rf = 0.40 
(hexane/AcOEt = 2:1); [α]D25 +117 (c 0.39, EtOH); 1H NMR (CDCl3, 400 MHz): δ = 
2.29–2.33 (m, 3H), 2.39–2.46 (m, 1H), 2.88–2.94 (m, 1H), 3.10–3.16 (m, 1H), 3.64–
3.66 (m, 1H), 3.92 (dd, J = 11.0, 5.9 Hz, 1H), 4.32–4.33 (m, 1H), 5.11–5.15 (m, 2H), 
5.25 (d, J = 15.5 Hz, 1H), 5.84 (ddd, J = 15.5, 11.0, 5.9 Hz, 1H), 7.17–7.21 (m, 1H), 
7.27 (t, J = 7.1 Hz, 2H), 7.36 (d, J = 7.1 Hz, 2H); 13C NMR (CDCl3, 100 MHz): δ = 
32.9, 44.5, 50.5, 67.8, 68.1, 86.3, 97.6, 116.1, 127.2, 127.4, 128.4, 136.3, 140.9; IR 
(KBr) 2940, 1640, 1490, 1450, 1300, 1090 cm–1; HRMS (FAB+): m/z calcd for 
C15H19N2O: 243.1497: [M+H]+; found: 243.1501.   
(R)-1-((1R,3R)-3-Phenylhexahydropyrazolo[1,2-a]pyrazol-1-yl)prop-2-en-1-ol (10) 
 5 
To a suspension of LiAlH4 (151 mg, 4.0 mmol) in THF (8.0 mL) was added a THF (2.0 
mL) solution of 3a (99% ee, 103 mg, 0.40 mmol) at 0 °C and the resultant suspension 
was stirred for 1 h under refluxing. After the reaction was cooled to 0 °C, H2O (0.15 
mL), 30% NaOH aq (0.15 mL), and H2O (0.45 mL) were subsequently added, followed 
by stirring for 30 min at rt. The mixture was filtered through a bed of Celite and the 
filtrate was condensed under reduced pressure. The residue was purified by column 
chromatography (SiO2, AcOEt only ~ AcOEt/MeOH = 10:1~5:1) to afford 10 (60 mg, 
61%) as a solid. Rf = 0.35 (AcOEt/MeOH = 5:1); [α]D25 +3 (c 0.61, EtOH); m.p. 122.0–
125.0 °C (recrystallized from AcOEt); 1H NMR (CDCl3, 400 MHz): δ = 2.02–2.14 (m, 
2H), 2.24–2.31 (m, 1H), 2.43–2.54 (m, 3H), 2.94–3.01 (m, 1H), 3.12 (brs, 1H), 3.17–
3.24 (m, 1H), 3.60 (br, 1H), 4.08–4.12 (m, 1H), 4.36 (brs, 1H), 5.19 (dd, J = 10.5, 1.4 
Hz, 1H), 5.37 (dd, J = 17.0, 1.4 Hz, 1H), 5.90 (ddd, J = 17.0, 10.5, 5.5 Hz, 1H), 7.24–
7.28 (m, 1H), 7.30 (t, J = 7.1 Hz, 2H), 7.39 (d, J = 7.1 Hz, 2H); 13C NMR (CDCl3, 100 
MHz): δ = 25.9, 35.3, 46.7, 51.0, 65.1, 67.1, 74.6, 115.5, 127.2, 127.7, 128.3, 139.0, 
139.6; IR (KBr) 3086, 2974, 1641, 1603, 1494, 1449, 1361, 1286, 1140, 1061, 932, 766 
cm–1; HRMS (DART): m/z calcd for C15H21N2O: 245.1654: [M+H]+; found: 245.1650.   
 (1R,3R)-1-((R)-1-Hydroxyallyl)-7-oxo-3-phenylhexahydro-1H-pyrazolo[1,2-a]pyrazole 
4-oxide (11) 
To a CH2Cl2 (2 mL) solution of 3a (99% ee, 52 mg, 0.20 mmol), mCPBA (70%, 48 mg, 
0.19 mmol) was added at 0 °C and the resulting solution was stirred at rt for 1 h. A sat. 
aqueous solution of NaHCO3 was added and the mixture was subsequently extracted 
with CHCl3. The aqueous layer was separated and extracted with CHCl3. The combined 
organic layers were dried over Na2SO4 and condensed under reduced pressure. The 
mixture was filtered through a bed of Celite and condensed under reduced pressure. The 
residue was purified by column chromatography (SiO2, hexane/AcOEt = 1:1 ~ AcOEt 
only ~ AcOEt/MeOH = 5:1~1:1) to give 11 as an oil. Rf = 0.30 (AcOEt/MeOH = 5:1); 
[α]D25 +30 (c 0.45, EtOH); 1H NMR (CDCl3, 400 MHz): δ = 1.44–1.53 (m, 1H), 2.10 
(br, 1H), 2.77–2.87 (m, 2H), 3.65–3.71 (m, 1H), 3.96–4.03 (m, 1H), 4.14–4.21 (m, 1H), 
4.24–4.26 (m, 1H), 4.90 (tt, J = 7.4, 1.4 Hz, 1H), 5.04 (d, J = 8.2 Hz, 1H), 5.24 (dt, J = 
10.5, 1.4 Hz, 1H), 5.49 (dt, J = 16.9, 1.4 Hz, 1H), 5.97 (ddd, J = 16.9, 10.5, 5.0 Hz, 1H), 
7.28–7.29 (m, 2H), 7.45–7.42 (m, 3H); 13C NMR (CDCl3, 100 MHz): δ = 32.1, 33.2, 
61.4, 63.0, 71.4, 88.4, 116.0, 129.4, 129.9, 131.0, 132.9, 138.9, 169.3; IR (KBr) 3400, 
2930, 1730, 1645, 1450, 1350, 1280, 1200, 980 cm–1; HRMS (DART): m/z calcd for 
C15H19N2O3: 275.1396: [M+H]+; found: 275.1395.    
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Figure 4. Proposed transition states during the 1,3-dipolar cycloaddition of an 












Table 1. Desymmetrization of 1,4-pentadiene-3-ol (1) by the stoichiometric asymmetric 











     (1.0 equiv)
3)
 (1.0 equiv)




Entry R’MgX n R  t/d Yield/%    ee/%[a] 
   1[b] MeMgBr 1.0 Ph a 2 50 98 
2 MeMgBr 1.0   2 57 99 
3 nBuMgCl 1.0   2 93 99 
4 nBuMgCl 1.0 pMeOC6H4 b 2 98 99 
5 nBuMgCl 1.0 pClC6H4 c 2 97 99 
6 nBuMgCl 1.0 nC5H11 d 2    14[c] 63 
7 nBuMgCl 3.0   2    33[c] 97 
8 nBuMgCl 1.0 cC6H11 e 3 80 99 
9 nBuMgCl 1.0 tBu f 3 56 98 
[a] Enantioselectivities were determined by HPLC analysis (Daicel CHIRALCEL OD-
H). [b] Solvent was MeCN instead of EtCN. [c] By-product 4, produced via 
rearrangement of 2d to an enamine intermediate, was obtained in 33% (Entry 6) and 





Table 2. Desymmetrization of 1,4-pentadiene-3-ol (1) by the catalytic asymmetric 1,3-




    (1.5 equiv) in EtCN
2
1) MgBr2 
     (1.0 equiv)
2) (R,R)-DIPT 
     (0.2 equiv)
4)
 (1.0 equiv)












Entry R’MgX R  t/d Yield/%     ee/%[a] 
1 nBuMgCl Ph a 5 30 84 
2 MeMgBr   2 68 95 
   3[b] MeMgBr   2 64 91 
4 MeMgBr pMeOC6H4 b   5.5 40 93 
5 MeMgBr pClC6H4 c   5.5 60 96 
6 MeMgBr nC5H11 d 2    13[c] 79 
   7[d] MeMgBr   2    10[c] 85 
8 MeMgBr cC6H11 e 2 69 95 
9 MeMgBr tBu f   5.5 75 98 
[a] Enantioselectivities were determined by HPLC analysis (Daicel CHIRALCEL OD-
H). [b] MgBr2 was not added in step 1. [c] By-product 4 was obtained in 24% (Entry 6) 




















      (3.0 equiv) in EtCN (1.0 equiv)
1) (R,R)-DIPT 
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